vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and indie Semiconductor, Inc. (INDI). Click either name above to swap in a different company.
indie Semiconductor, Inc. is the larger business by last-quarter revenue ($55.5M vs $38.3M, roughly 1.4× ImmunityBio, Inc.). On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 2.6%).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
indie Semiconductor is a fabless semiconductor manufacturer focused on designing high-performance mixed-signal and embedded system-on-chip solutions for the automotive industry. Its products support advanced driver assistance systems, in-vehicle infotainment, connected car, and electric vehicle applications, serving global auto OEMs and tier 1 suppliers across major global markets.
IBRX vs INDI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $55.5M |
| Net Profit | $-61.9M | — |
| Gross Margin | 99.0% | 38.0% |
| Operating Margin | -169.0% | -70.1% |
| Net Margin | -161.8% | — |
| Revenue YoY | 407.0% | 2.6% |
| Net Profit YoY | -4.7% | — |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $55.5M | ||
| Q4 25 | $38.3M | $58.0M | ||
| Q3 25 | $32.1M | $53.7M | ||
| Q2 25 | $26.4M | $51.6M | ||
| Q1 25 | $16.5M | $54.1M | ||
| Q4 24 | $7.6M | $58.0M | ||
| Q3 24 | $6.1M | $54.0M | ||
| Q2 24 | — | $52.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-61.9M | $-31.2M | ||
| Q3 25 | $-67.3M | $-38.3M | ||
| Q2 25 | $-92.6M | $-39.0M | ||
| Q1 25 | $-129.6M | $-34.5M | ||
| Q4 24 | $-59.2M | $-34.4M | ||
| Q3 24 | $-85.7M | $-49.7M | ||
| Q2 24 | — | $-19.2M |
| Q1 26 | — | 38.0% | ||
| Q4 25 | 99.0% | 37.3% | ||
| Q3 25 | 99.4% | 40.1% | ||
| Q2 25 | 99.5% | 40.6% | ||
| Q1 25 | 99.6% | 41.7% | ||
| Q4 24 | — | 42.6% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | — | 42.2% |
| Q1 26 | — | -70.1% | ||
| Q4 25 | -169.0% | -58.5% | ||
| Q3 25 | -173.5% | -71.4% | ||
| Q2 25 | -269.8% | -83.3% | ||
| Q1 25 | -390.1% | -72.0% | ||
| Q4 24 | -919.0% | -58.4% | ||
| Q3 24 | -1314.3% | -92.5% | ||
| Q2 24 | — | -70.0% |
| Q1 26 | — | — | ||
| Q4 25 | -161.8% | -53.8% | ||
| Q3 25 | -209.8% | -71.3% | ||
| Q2 25 | -350.3% | -75.6% | ||
| Q1 25 | -784.9% | -63.9% | ||
| Q4 24 | -783.4% | -59.2% | ||
| Q3 24 | -1404.0% | -92.1% | ||
| Q2 24 | — | -36.6% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.06 | $-0.16 | ||
| Q3 25 | $-0.07 | $-0.19 | ||
| Q2 25 | $-0.10 | $-0.20 | ||
| Q1 25 | $-0.15 | $-0.18 | ||
| Q4 24 | $-0.08 | $-0.18 | ||
| Q3 24 | $-0.14 | $-0.28 | ||
| Q2 24 | — | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $174.4M |
| Total DebtLower is stronger | — | $402.8M |
| Stockholders' EquityBook value | $-500.5M | $348.9M |
| Total Assets | $501.9M | $869.6M |
| Debt / EquityLower = less leverage | — | 1.15× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $174.4M | ||
| Q4 25 | $242.8M | $145.5M | ||
| Q3 25 | $257.8M | $160.9M | ||
| Q2 25 | $153.7M | $192.6M | ||
| Q1 25 | $61.6M | $236.6M | ||
| Q4 24 | $149.8M | $274.2M | ||
| Q3 24 | $130.4M | $96.9M | ||
| Q2 24 | — | $112.3M |
| Q1 26 | — | $402.8M | ||
| Q4 25 | — | $353.4M | ||
| Q3 25 | — | $353.5M | ||
| Q2 25 | — | $352.5M | ||
| Q1 25 | — | $379.0M | ||
| Q4 24 | — | $381.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $348.9M | ||
| Q4 25 | $-500.5M | $358.0M | ||
| Q3 25 | $-524.3M | $369.2M | ||
| Q2 25 | $-570.7M | $390.4M | ||
| Q1 25 | $-591.4M | $405.6M | ||
| Q4 24 | $-489.1M | $417.9M | ||
| Q3 24 | $-745.1M | $458.6M | ||
| Q2 24 | — | $470.7M |
| Q1 26 | — | $869.6M | ||
| Q4 25 | $501.9M | $840.8M | ||
| Q3 25 | $519.0M | $855.1M | ||
| Q2 25 | $402.1M | $867.6M | ||
| Q1 25 | $303.8M | $909.0M | ||
| Q4 24 | $382.9M | $941.4M | ||
| Q3 24 | $364.6M | $797.5M | ||
| Q2 24 | — | $797.3M |
| Q1 26 | — | 1.15× | ||
| Q4 25 | — | 0.99× | ||
| Q3 25 | — | 0.96× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 0.91× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | — |
| Free Cash FlowOCF − Capex | $-71.3M | — |
| FCF MarginFCF / Revenue | -186.2% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-70.4M | $-14.4M | ||
| Q3 25 | $-68.9M | $-6.2M | ||
| Q2 25 | $-79.7M | $-7.6M | ||
| Q1 25 | $-85.9M | $-29.0M | ||
| Q4 24 | $-85.1M | $-6.7M | ||
| Q3 24 | $-98.8M | $-22.8M | ||
| Q2 24 | — | $-19.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-71.3M | $-16.1M | ||
| Q3 25 | $-69.6M | $-10.3M | ||
| Q2 25 | $-80.8M | $-13.6M | ||
| Q1 25 | $-87.0M | $-31.4M | ||
| Q4 24 | $-87.3M | $-8.6M | ||
| Q3 24 | $-101.6M | $-29.3M | ||
| Q2 24 | — | $-23.4M |
| Q1 26 | — | — | ||
| Q4 25 | -186.2% | -27.8% | ||
| Q3 25 | -217.2% | -19.2% | ||
| Q2 25 | -305.9% | -26.4% | ||
| Q1 25 | -526.9% | -58.0% | ||
| Q4 24 | -1155.4% | -14.8% | ||
| Q3 24 | -1663.2% | -54.3% | ||
| Q2 24 | — | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | 3.0% | ||
| Q3 25 | 2.3% | 7.8% | ||
| Q2 25 | 4.1% | 11.6% | ||
| Q1 25 | 6.8% | 4.4% | ||
| Q4 24 | 28.0% | 3.2% | ||
| Q3 24 | 45.7% | 12.1% | ||
| Q2 24 | — | 7.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IBRX
Segment breakdown not available.
INDI
| Product revenue | $51.6M | 93% |
| Contract revenue | $3.9M | 7% |
